Mallinckrodt plc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of therapies in areas of acute and chronic care. The company’s product portfolio spans branded therapeutics, specialty generics and nuclear imaging agents, serving hospitals, clinics and retail pharmacies. Mallinckrodt operates manufacturing facilities in the United States and Europe and maintains a global commercial footprint, delivering products to patients in more than 60 countries worldwide.
The company’s core business activities include production of immunotherapy and autoimmune disease treatments, pain management therapies and specialty generics. A notable product in its portfolio is Acthar® Gel, an injectable drug approved for several rare and serious inflammatory conditions. In its nuclear imaging segment, Mallinckrodt supplies Technetium-99m generators and related radiopharmaceuticals that support diagnostic procedures in cardiology, oncology and neurology. Alongside its branded offerings, Mallinckrodt markets a range of generic injectables and oral medications, addressing hospital requirements for cost-effective therapeutics.
Mallinckrodt’s origins trace back to Mallinckrodt Chemical Works, founded in 1867, with the modern pharmaceutical business established through a spin-off from Covidien plc in 2013. Headquartered in Dublin, Ireland, the company underwent a financial restructuring in 2020 to resolve legacy litigation and reinforce its balance sheet. Under its current structure, Mallinckrodt continues to invest in manufacturing capabilities, research and development, and strategic partnerships to advance its pipeline and expand access to critical therapies worldwide.
AI Generated. May Contain Errors.
